This is a working overview of MC4R, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
| Property | Value | Notes |
|---|---|---|
| Research code | PT-141 | Used in early literature before the generic name became common |
| Generic name | Bremelanotide | International nonproprietary name |
| Peptide class | Cyclic heptapeptide | Seven residues joined by a lactam bridge |
| Primary receptor | MC4R | Lower affinity reported at MC1R, MC3R and MC5R |
| Route studied clinically | Subcutaneous injection | Intranasal route was abandoned after pressor effects |
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
== Uses == Synthetic platelets have diverse therapeutic applications, including treating hemostasis in trauma care, clotting disorders, and immune responses in conditions such as thrombosis, inflammation, and cancer. Originally researched to replicate the biochemistry and cell and molecular biology of natural platelets, platelet-mimicking particles are now in preclinical development for multiple therapeutic applications with specialized drug delivery mechanisms. The need for these particles is informed by increasing rates of reported thrombocytopenia cases and clinical bleeding syndrome diagnoses such as von Willebrand disease or Glanzmann thrombasthenia. Early treatment solutions of the mid-late twentieth century were not based upon current findings in nanoparticle drug delivery technologies, thus lacking the ability to overcome primary limitations of natural platelets. With a diverse assortment of platelet-mimicking particle formulations under testing, their use can be widespread to multiple clinical diagnoses and areas—antimicrobial platelets, cancer, hemorrhage and trauma, bleeding disorders, and cholesterol clearance.
=== France === France was obligated to join Russia due to their 1893 military alliance. French bankers did have financial interests in Russia, especially in railroads. However, France had no territorial ambitions in Manchuria, as its sphere of influence was in southern China (see Sino-French War). The French actually had cordial relations with the Japanese: French military advisors had been sent to train the Imperial Japanese Army since the expedition in 1867 and a number of Japanese ships were built in French shipyards. However, France did not wish to be diplomatically isolated, as she had been previously during Bismarck’s diplomatic quarantine of revanchist France after the Franco-Prussian War, especially given the growing power of Germany.
July 13, 1983: Law on the rights and obligations of civil servants. July 13, 1983: Law amending the Labor Code and the Penal Code concerning professional equality between women and men (Roudy Law): gender equality in the workplace. January 4, 1984: Law amending the Labor Code concerning parental education leave and part-time work for parents of young children. February 29, 1984: Decree creating, under the Minister Delegate to the Prime Minister for Women's Rights, a terminology commission responsible for studying the feminization of titles and functions, and more generally, vocabulary concerning women's activities. May 7, 1984: Law on acquiring French nationality through marriage. July 12, 1984: Bill concerning alimony. December 4, 1984: Decree on work permits issued to foreign workers. December 22, 1984: Law on the intervention of family benefits agencies for recovering unpaid alimony. January 4, 1985: Law on measures in favor of young families and large families. May 31, 1985: Decree on the responsibilities of the Minister for Women's Rights; this results in the ministry's autonomy. December 23, 1985: Law establishing equality between spouses in matrimonial regimes and between parents in managing the property of their minor children. January 6, 1986: Law adapting health and social legislation to the transfer of responsibilities in social and health assistance. March 11, 1986: Circular on the feminization of job titles, roles, ranks, or honors. May 2, 1986: Decree concerning the Delegate for Women's Affairs. December 29, 1986: Law relating to the family.
== Nutrition and health effects == Lamb and mutton are forms of red meat. Red meat is a good source of protein, iron, zinc, and vitamins B1, B2, B6, and B12. According to the International Agency for Research on Cancer (IARC), unprocessed red meat probably leads to an increased risk of cancer, particularly colorectal cancer. Studies have also linked red meat with higher risks of cardiovascular disease and type 2 diabetes. If meat is processed, such as by salting, curing, or smoking, health risks further increase. The World Cancer Research Fund recommends limiting red meat to no more than three servings per week.
=== Monoamine oxidase inhibitor === Monoamine oxidase inhibitors, have historically been plagued by questionable efficacy (although early studies used dosages now considered too low) and life-threatening adverse effects. They are still used only rarely, although newer agents of this class (RIMA), with a better side effect profile, have been developed. In older patients TCAs and SSRIs are of the same efficacy. However, there are differences between TCA related antidepressants and classical TCAs in terms of side effect profiles and withdrawal when compared to SSRIs. There is evidence a prominent side-effect of antidepressants, emotional blunting, is confused with a symptom of depression itself. The cited study, according to Professor Linda Gask was:
Sources: en.wikipedia.org
Helium (from Ancient Greek: ἥλιος, romanized: helios, lit. 'sun') is a chemical element; it has symbol He and atomic number 2. It is a colorless, odorless, non-toxic, inert, monatomic gas and the first in the noble gas group in the periodic table. Its boiling point is the lowest among all the elements, and it does not have a melting point at standard pressures. It is the second-lightest and second-most abundant element in the observable universe, after hydrogen. It is present at about 24% of the total elemental mass, which is more than 12 times the mass of all the heavier elements combined. Its abundance is similar to this in both the Sun and Jupiter, because of the very high nuclear binding energy (per nucleon) of helium-4 with respect to the next three elements after helium. This helium-4 binding energy also accounts for why it is a product of both nuclear fusion and radioactive decay. The most common isotope of helium in the universe is helium-4, the vast majority of which was formed during the Big Bang. Large amounts of new helium are created by nuclear fusion of hydrogen in stars. Helium was first detected as an unknown, yellow spectral line signature in sunlight during a solar eclipse in 1868 by Georges Rayet, Captain C. T. Haig, Norman R. Pogson, and Lieutenant John Herschel, and was subsequently confirmed by French astronomer Jules Janssen. Janssen is often jointly credited with detecting the element, along with Norman Lockyer. Janssen recorded the helium spectral line during the solar eclipse of 1868, while Lockyer observed it from Britain.
Because testing methods differ between laboratories, reference ranges may vary. A positive anti-U1 RNP antibody test should always be interpreted together with a patient's symptoms and other significant research.
=== Absence === "Silent" myocardial infarctions can happen without any symptoms at all. These cases can be discovered later on electrocardiograms, using blood enzyme tests, or at autopsy after a person has died. Such silent myocardial infarctions represent between 22 and 64% of all infarctions, and are more common in the elderly, in those with diabetes mellitus and after heart transplantation. In people with diabetes, differences in pain threshold, autonomic neuropathy, and psychological factors have been cited as possible explanations for the lack of symptoms. In heart transplantation, the donor heart is not fully innervated by the nervous system of the recipient.
The four substrates of this enzyme are anthranilic acid, reduced nicotinamide adenine dinucleotide (NADH), oxygen, and a proton. Its products are catechol, carbon dioxide, oxidised NAD+, and ammonia. The enzyme can also use nicotinamide adenine dinucleotide phosphate as a cofactor. This enzyme is an oxidoreductase which uses molecular oxygen as oxidant and incorporates its atoms into the product. The systematic name of this enzyme class is anthranilate,NAD(P)H:oxygen oxidoreductase (1,2-hydroxylating, deaminating, decarboxylating). Other names in common use include anthranilate hydroxylase, anthranilic hydroxylase, and anthranilic acid hydroxylase. It participates in three metabolic pathways: benzoate degradation via hydroxylation, carbazole degradation, and nitrogen metabolism. It requires ferrous iron.
=== Mechanical behavior === The mucus of the gastropods contained positively charge polypeptides and negatively charged polysaccharides that form a dissipative matrix. This contributes to the mechanical strength and toughness of the hydrogel. Tensile strength of dried snail mucus gel of the Achatina fulica species reached 82.59 ± 7.39 kPa. In addition to tensile properties, gastropod adhesives have significant pel strength. This high peel resistance is due to the double interpenetrating network structure, where the deformable network dissipates energy whole the stiffer network maintains structural integrity. As a result, the adhesive can sustain large deformations and distribute stress over a larger area. The combination of energy dissipation and strong interfacial bonding allows the adhesive to adhere to wet and irregular biological surfaces.
Sources: en.wikipedia.org
These new RNA transcripts are then used to repeat the selection cycle many times, thus eventually producing a homogeneous pool of RNA aptamers capable of highly specific, high-affinity target binding.
Maybe King Crimson will speak to him in the future in some way, and will revive its head with who-knows-what line up?" At a post-screening Q&A session for In the Court of the Crimson King, Fripp referred to the seven-member 2021 line-up of King Crimson as "the final incarnation" of the band. Asked if there could ever be a line-up that did not include him, he answered negatively, stating "I see the whole. I see the music. I see the musicians. I see the audience and I see the music industry [...] and you have to engage with all of that to have the overview. So that's the quick answer".
Common Foreign and Security Policy, including the Common Security and Defence Policy (funded by the European Defence Fund and European Defence Agency), membership of NATO, the United Nations TFEU art 214, Directorate-General for European Civil Protection and Humanitarian Aid Operations European Neighbourhood Policy Common Commercial Policy (EU), European Commissioner for Trade, European Union free trade agreements, World Trade Organization TFEU art 218, advisory opinion procedure on international agreements
=== Public security === The Federal Government presented a proposed constitutional amendment (PEC) aimed at modernizing and integrating public security in the country. The initiative, led by the ministry of justice and public security, Ricardo Lewandowski, seeks to strengthen the fight against organized crime and improve cooperation among the Union, states and municipalities. Among the main points are the creation of a Unified Public Security System (SUSP) with constitutional status, the expansion of the responsibilities of the Federal Police and the Federal Highway Police – which would be renamed the Federal Ostensive Police – and the consolidation of permanent financial instruments, such as the National Public Security and Penitentiary Policy Fund, guaranteeing stable resources for the sector. The government argues that the proposal does not remove the autonomy of the states, but seeks to promote greater coordination and efficiency in police action, especially in the face of the advance of criminal factions operating beyond state borders. Even so, the text faces resistance from sectors of the right and the opposition. Despite the criticism, the Ministry of Justice states that the proposal was built in dialogue with governors and specialists, and that it represents an effort to make the fight against crime more integrated, technological and effective throughout the national territory.
== Awards and honors == 1990 - Robert J. and Claire Pasarow Foundation Medical Research Award 1990 - American Association for Cancer Research - G.H.A. Clowes Memorial Award Archived 2017-10-24 at the Wayback Machine 1991 - Honorary doctorate in medicine from Lund University, Sweden 1995 - Nobel Fellow at the Karolinska Institutet in Stockholm 1997 - Gairdner Foundation International Award 1998 - Jacobaeus International Prize 2003 - Jubilee Lecturer, Biochemical Society 2005 - Japan Prize in Cell Biology 2012 - Thomson Reuters Citation Laureate Knight of the Order of the White Rose of Finland Commander of the Order of the Lion of Finland 2022 - Albert Lasker Award for Basic Medical Research. 2023 - Fellow of the American Association for Cancer Research. Member of National Academy of Sciences National Academy of Medicine American Academy of Arts and Sciences European Molecular Biology Organization
Sources: en.wikipedia.org
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.
MC4R is generally described as the principal target, based on binding affinity and functional assays. Activity at MC1R, MC3R and MC5R is reported as weaker. Receptor selectivity is one reason the compound was pursued for central rather than vascular effects.
Both are synthetic melanocortin analogues built on a similar cyclic peptide scaffold. Bremelanotide is described in the literature as a metabolite-derived analogue of melanotan II rather than the same substance. The two differ in terminal modifications, which affect half-life and receptor profile.
PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.